WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Last trade$2.86
Day change-$0.01 (-0.35%)
Day range$2.79 – $3.00
Volume1,738,343
Market cap$566M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$566.05M
Price / earnings
—
Price / book
1.41×
Price / sales
7.98×
EV / sales
5.2×
EV / EBITDA
-1.64×
Profitability
Earnings per share
-$1.07
Return on assets
-41.45%
Return on equity
-52.38%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.38×
Quick ratio
8.38×
Cash ratio
3.6×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$208.39M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for WVE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$13.16M
$2.27M
$38.25M
$17.25M
$7.61M
$8.7M
$9.18M
$83.75M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$13.16M
$2.27M
$38.25M
$17.25M
$7.61M
$8.7M
$9.18M
$83.75M
Selling, general and administrative
$25.36M
$24.78M
$22.1M
$20.9M
$18.09M
$17.99M
$18.36M
$16.14M
Research and development
$53.84M
$51.29M
$47.44M
$52.81M
$45.87M
$43.47M
$40.62M
$44.65M
Total operating expenses
$79.21M
$76.07M
$69.54M
$73.71M
$63.96M
$61.46M
$58.98M
$60.78M
Operating income
-$66.05M
-$73.8M
-$31.3M
-$56.47M
-$56.35M
-$52.76M
-$49.8M
$22.97M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$61.91M
-$69.36M
-$26.09M
-$53.18M
-$53.85M
-$50.47M
-$46.88M
$29.25M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$61.91M
-$69.36M
-$26.09M
-$53.18M
-$53.85M
-$50.47M
-$46.88M
$29.25M
Net income attributable to common shareholders
-$61.91M
-$69.36M
-$26.09M
-$53.18M
-$53.85M
-$50.47M
-$46.88M
$29.25M
EBITDA
-$65.17M
-$72.94M
-$30.46M
-$55.62M
-$55.5M
-$51.89M
-$48.93M
$23.87M
Basic earnings per share
-$0.30
-$0.34
-$0.13
-$0.29
-$0.32
-$0.31
-$0.29
$0.18
Diluted earnings per share
-$0.30
-$0.34
-$0.13
-$0.29
-$0.32
-$0.31
-$0.29
$0.18
Recent news
Company coverage with links to the original publishers.
GSK is expected to report a year-over-year earnings decline of 5.4% to $1.40 per share for Q3 2026, despite revenues rising 2.4% to $11.8 billion. With a negative Earnings ESP of -4.56% and Zacks Rank #4, the stock is not considered a compelling earnings-beat candidate. The company has historically beaten estimates in recent quarters, but recent analyst revisions suggest bearish sentiment on near-term earnings prospects.
Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.
The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.
Wave Life Sciences regained full rights to WVE-006 from GSK for treating alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder. Wave plans to accelerate the registrational strategy and pursue an accelerated FDA approval pathway, with regulatory feedback expected mid-2026. Clinical trial data from the RestorAATion-2 trial is on track for Q1 2026. WVE stock rose 4.48% on the announcement.
The article highlights three stocks showing potential for upside momentum in 2026 based on golden cross technical signals and fundamental analysis: Sun Communities, Darling Ingredients, and Wave Life Sciences.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.